As a result of the link to developing breasts after taking Risperdal, lawsuits were filed on behalf of the children and adolescents who suffered from the abnormal growth of male breast tissue and the increased production of prolactin. The first Risperdal lawsuit ended in a $2.5 million loss for Johnson & Johnson.